MANHATTAN PHARMACEUTICALS TO PRESENT AT THE 5TH ANNUAL NORTH AMERICA FORUM FOR INVESTING AND PARTNERING IN BIOTECH AND MEDTECH
Mar 09, 2006
NEW YORK, NY MAR. 9, 2006 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) announced today that Douglas Abel, president and chief executive officer, will present at the 5th Annual North America Forum for Investing and Partnering in Biotech and Medtech. Mr. Abel's presentation will take place on Monday, March 13, 2006 at 3:50 pm EST at the Fairmont Copley Plaza in Boston, MA.
Mr. Abel will provide an overview of the company and an update on its clinical development programs, including Oleoyl-estrone (OE), Manhattan Pharmaceuticals' orally administered small molecule in development for the treatment of obesity.
To access the live audio webcast for this presentation please go to http://www.investorcalendar.com/CEPage.asp?ID=102424 approximately 15 minutes prior to the presentation in order to register and download any necessary software. A replay of the audio presentation will be available following the event at http://www.manhattanpharma.com. Additional information about the forum may be found at: www.sachsforum.com.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc. (www.manhattanpharma.com), a development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.